Announcement PDF ASX AND MEDIA RELEASE Investment Research Report 21 July 2016, Perth, Australia: Race Oncology Ltd (ASX: RAC) today announced the publication of a commissioned report on Race Oncology by research house, Independent Investment Research (IIR). The IIR report is available on the Company’s website at: www.raceoncology.com About Race Oncology Race Oncology is a specialty pharmaceutical company, whose business model is to pursue later stage assets, principally in the cancer field. The Company’s first important asset is a chemotherapy drug, called Bisantrene, which was the subject of more than 40 phase II clinical studies during the 1980s and 1990s. Race Oncology owns recent patent filings on Bisantrene and has secured Orphan Drug Designation in the US. The Company’s goal is to complete final development of Bisantrene and bring this valuable cancer drug to market. For more information, contact: Peter Molloy Managing Director T: +61 (0) 3 9097 1656 M: +61 (0) 418 174 816 Race Oncology Limited, ABN 61 149 318 749 Level 2, 50 Kings Park Road, West Perth WA 6005 www.raceoncology.com